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Abstract
Background: Glaucoma is a major cause of blindness worldwide and an increasingly significant
global health problem. Glaucoma prevention and management efforts have been challenging due to
inherent difficulty in developing a simple and cost-effective screening plan, limited access to health
care and educational resources, poverty, and inadequate knowledge of the disease, particularly in
developing countries. Starting in 2004 the Tilganga Eye Centre in Kathmandu, Nepal has provided
targeted glaucoma screening, treatment, and education through a combination of clinical outreach
programs and educational activities for patients.
Methods: A simple, age-based glaucoma screening algorithm was incorporated into three one-day
cataract screening clinics. Using this algorithm, patients who were newly diagnosed with glaucoma
were referred to TEC, where medication and surgery were provided free of charge through private
donor funding. In addition, we describe two ongoing educational programs for increasing glaucoma
awareness: an annual Glaucoma Awareness Week (which includes free screening, treatment, and
counseling), and a repeating lecture series which generates new counselors.
Results: From 2004 to 2007 screening at the annual Glaucoma Awareness Week resulted in the
diagnosis of 120 individuals with glaucoma, or 7.6% of total registrants. Attendance increased
annually with a trend toward an increasing number of returning patients but a decreasing
percentage of newly diagnosed patients, though the absolute numbers have remained relatively
stable (range 21 to 38). Data from the three one-day screening clinics in 2006 show that
approximately 2 to 4% of patients 50 years of age or older per clinic were newly diagnosed with
POAG.
Conclusion: This multi-faceted approach appears to successfully identify individuals with glaucoma
and provide treatment to those who would otherwise not be able to afford it. While more data is
needed to validate this model, specifically regarding the effectiveness of educational activities, long-
term visual outcomes, and medication compliance, it may serve as a useful framework for other
developing countries with similarly limited resources.
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The term glaucoma encompasses a group of ophthalmic
diseases that are believed to share the common patho-
physiology of elevated intraocular pressure (IOP), or
abnormal sensitivity to high-normal IOP, resulting in
damage to the nerve fiber layer of the retina and irreversi-
ble vision loss [1]. The two most common forms of the
disease are primary open angle glaucoma (POAG) and
primary angle closure glaucoma (PACG), with variable
patterns of disease prevalence in different ethnic
groups[2]. The World Health Organization (WHO)
reported in 2002 that glaucoma accounted for approxi-
mately 4.6 million cases, or 12.3%, of the 37 million cases
of blindness worldwide, making it the second most com-
mon cause of blindness after cataract[3]. Furthermore, it
has been estimated that over 60 million people world-
wide will have glaucoma by 2010, resulting in 8.4 million
cases of bilateral blindness[2]. These figures plainly sug-
gest that glaucoma is a disease of particular public health
significance; indeed, blindness and low vision, independ-
ent of cause, are important global health issues because
they confer increased morbidity and mortality, decreased
quality of life, and substantial economic productivity loss
[4-8]. Due to the irreversible nature of the vision loss that
occurs with glaucoma, management strategies must focus
by necessity upon early detection and prevention of dis-
ease progression through strict control of IOP. However,
these goals are limited by the fact that a simple and cost-
effective screening plan for glaucoma has yet to be devel-
oped [9-12]. The prevention of glaucoma in developing
and developed countries alike is further hindered by fac-
tors such as limited access to health care, poverty, limited
formal education, and inadequate knowledge or under-
standing of the disease [13,14].
The country of Nepal faces these obstacles on a significant
scale. The United Nations 2006 Human Development
Report ranked Nepal 138th out of 177 countries based
upon its human development index (HDI) which takes
into consideration life expectancy as well as indicators of
education and standard of living [15]. In addition,
Nepal's predominantly mountainous terrain (which com-
prises the northern two-thirds of the country) and variable
weather conditions contribute to a total road network that
is the lowest in the region according to the World Bank,
with only 36% of the population having access to all-
weather roads and the health care facilities that they may
lead to[16]. According to estimates from the Nepal Blind-
ness Survey (conducted from 1980 to 1981), glaucoma
accounted for 3,820 cases, or 3.2%, of bilateral blindness
in Nepal[17]. More recent WHO regional data (including
Nepal, India, Pakistan, and Bangladesh) places the
number at 9%2; notably, neither figure accounts for the
presumably greater number of individuals with less
advanced disease. To address this growing problem, the
Tilganga Eye Centre (TEC), a tertiary eye hospital located
in Kathmandu, Nepal, initiated a multi-faceted approach
to glaucoma screening, treatment, and education, specifi-
cally through the incorporation of glaucoma screening
into established clinical outreach programs and educa-
tional activities with referral for treatment as needed. This
model may be of interest as a framework for other devel-
oping countries where health care and educational
resources are similarly limited.
Methods
1. Screening clinics
TEC conducts two different types of outreach programs:
microsurgical eye clinics (almost exclusively cataract) in
remote areas of Nepal and neighboring countries that typ-
ically last several days, and one-day cataract screening
clinics in villages closer to the capital of Kathmandu that
are accessible by road. Made possible through the finan-
cial support of private donors, these programs target
patients who have not sought out care due to limited or
non-existent local health care facilities, financial con-
straints, or simply lack of awareness. In anticipation of the
one-day screening clinics, local organizers are recruited
and invited to TEC the week prior to the clinic for instruc-
tion and education about the objectives of the clinic.
These organizers are responsible for advertising the clinic
(e.g. through posters, flyers, or door-to-door visits), man-
aging volunteers, procuring an appropriate facility, and
the transportation of patients to TEC. In turn, TEC pro-
vides a team of ophthalmologists, ophthalmic assistants
who have completed three years of university-affiliated
training, free medication, and diagnostic equipment such
as portable slit lamps. The clinics represent excellent
opportunities for the incorporation of "opportunistic"
glaucoma screening, which was performed at three differ-
ent one-day clinics and facilitated by the addition of a Per-
kins applanation tonometer (Haag-Streit®) and frequency
doubling technology (FDT) perimeter (Humphrey/Zeiss/
Welch Allyn®). A simple algorithm was developed in
which patients are initially triaged for a screening exami-
nation performed by either an ophthalmologist or an
ophthalmic assistant, depending on whether the patient is
above or below 50 years of age, respectively (Figure 1).
This age cutoff was chosen based upon the strong associa-
tion of glaucoma prevalence with increasing age and has
been selected as a reasonable cutoff in other screening
programs [10,18,19]. An ophthalmic assistant performed
a flashlight examination of the anterior segment and dis-
tant direct ophthalmoscopy to detect media opacities on
all subjects below 50 years of age. Patients with decreased
visual acuity, corneal haze, cataract, shallow anterior
chamber, or signs of PACG (e.g. iris atrophy, fixed pupils)
are referred to the screening clinic ophthalmologist. FDT
perimetry, applanation tonometry, and dilated fundu-
scopic examination were performed on all patients 50Page 2 of 7
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patients below 50 years of age. Patients with shallow ante-
rior chambers as detected by penlight or slit lamp exami-
nation (Van Herick method) were preferentially referred
to TEC for gonioscopy. Patients who were newly diag-
nosed with glaucoma at the screening clinic (or any other
eye disease requiring further management) were also
referred to TEC, where medication, and surgery if indi-
cated, were provided free of charge through the generosity
of private donors.
2. Glaucoma Awareness Week
Since 2004, TEC has hosted an annual Glaucoma Aware-
ness Week in either March or April when weather condi-
tions are most favorable for those patients traveling long
distances. The event is co-sponsored by the Glaucoma
Support Group of Nepal (GSGN) which was founded in
2003 and is a member of the World Glaucoma Patient
Association (WGPA). Its members include glaucoma
patients and their families, health care providers, and
social workers. The objectives of the group are to educate
glaucoma patients and their families about the disease, to
promote public awareness of glaucoma, and to provide
Patient encounter algorithm utilized at one day screening clinicsFigure 1
Patient encounter algorithm utilized at one day screening clinics. FDT = frequency doubling technology; IOP = 
intraocular pressure; TEC = Tilganga Eye Centre. †Patients with shallow anterior chambers are referred to TEC for gonios-
copy instead.
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treatment.
During this week glaucoma screening and any necessary
treatment are provided free of charge. Compared to the
one-day screening clinics, a more thorough standard eye
examination is performed, including measurement of vis-
ual acuity using a Snellen chart, slit lamp examination,
applanation tonometry, and fundus examination with a
90 diopter lens. All glaucoma suspects and newly diag-
nosed patients subsequently undergo disc photography,
optical coherence tomography (OCT), and FDT perime-
try. All patients who are newly diagnosed with glaucoma
receive counseling from ophthalmic assistants and patient
members of the GSGN, are enrolled in the GSGN and
Patient Education Program lecture series, and are pro-
vided with free samples of medication (typically a topical
beta-blocker, made possible in part by donations directly
from pharmaceutical companies). Returning patients are
also eligible to receive free interval evaluation, medica-
tion, and repeated counseling which emphasizes the
importance of compliance with therapy. Patients who
have more advanced disease requiring multiple medica-
tions or who live far away such that annual follow-up may
be prohibitive are scheduled for free surgery (trabeculec-
tomy). Ophthalmic assistants and students have created
educational posters about glaucoma, and copies of a
patient glaucoma handbook written in Nepali are availa-
ble for purchase at a reasonable cost with proceeds rein-
vested in further educational and treatment efforts. In
addition, a prize raffle has been held during previous
Glaucoma Awareness Weeks to supplement fundraising
efforts, with raffle tickets printed with educational mes-
sages such as risk factors for glaucoma. The GSGN pub-
lishes an annual report summarizing these activities and
efforts, and the event has received local television, radio,
and newspaper coverage, with patient attendance increas-
ing in each of the four years since its inception. Approxi-
mately 90% of patients are from Kathmandu and the
remaining 10% from villages in or near the Kathmandu
valley.
3. Patient Education Program
Another important educational effort is the Patient Educa-
tion Program, comprised of six lectures which take place
at TEC on a selected Saturday morning every two months.
The series is provided free of charge and is attended by
members of the GSGN. Topics presented by ophthalmol-
ogists include an introduction to the GSGN, a discussion
of glaucoma including risk factors, signs, symptoms, treat-
ment modalities, diagnostic tools used in the diagnosis of
glaucoma, instruction on how to properly administer eye
drops, possible side effects of glaucoma medications,
childhood glaucoma, new advances in glaucoma research,
and the sharing of experiences by patients with glaucoma.
At the end of each session attendees who have the finan-
cial means are encouraged to make a small donation
towards a fund that supports treatment for poor patients
throughout the year. In addition, some of the private
donors mentioned in the "Screening Clinics" section are
themselves glaucoma patients who attend our educa-
tional classes. These sponsors are again approached when
new glaucoma patients are identified from screening clin-
ics and are asked if they will further support medication
for a year or more to one or more patients. Upon comple-
tion of the entire Patient Education Program a short quiz
is administered, and those individuals who perform satis-
factorily are able to become counselors for other glau-
coma patients during Glaucoma Awareness Week. The
series repeats each year, and starting in 2006 has been
broadcast on a local FM radio channel to reach a wider
audience.
Results
From 2004 to 2007 screening at the annual Glaucoma
Awareness Week has resulted in the diagnosis of 120 indi-
viduals with glaucoma, or 7.6% of total registrants (Table
1). Attendance has increased annually with a trend toward
an increasing number of returning patients (from 145 in
2004 to 342 in 2007). There has also been a trend toward
a decreasing percentage of newly diagnosed patients,
though the absolute numbers have remained relatively
stable (range 21 to 38). Data from the three one-day
screening clinics in 2006 show that approximately 2–4%
of patients 50 years of age or older per clinic were newly
diagnosed with POAG (Table 2).
Discussion and Conclusion
Glaucoma is a public health issue of increasing impor-
tance as the global population increases in both age and
number. While our limited data show that the programs
described above are identifying undiagnosed glaucoma
patients and benefiting individuals who would otherwise
not be able to afford treatment, more data is needed to
validate this approach. For example, an analysis of the
effectiveness of educational activities could be performed
through the use of surveys. It would also be important to
know how many of the individuals referred to KEC for fur-
ther management actually follow-up so that barriers to
access can be better identified and addressed. A more cur-
rent estimate of the prevalence of glaucoma in Nepal
would also be helpful, as it is unclear if our Glaucoma
Awareness Week data approximate regional glaucoma
prevalence (such a study is currently being conducted in
the city of Bhaktapur). Finally, and perhaps most impor-
tantly, more data is needed regarding medication compli-
ance. Ensuring the continued availability of medication
along with patient compliance are problems inherent in
the management of glaucoma in the developing world, or
any other chronic disease for that matter. Long term sup-Page 4 of 7
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involves soliciting continued support from donors. While
annual free samples will not prevent blindness, they are
an effective means to lessen the financial burden on
patients and donors alike, as well as to motivate estab-
lished patients to return for evaluation of disease progres-
sion and reinforcement of educational messages.
More extensive analysis of these programs would not only
help to identify areas for improvement, but might also
suggest different management approaches altogether. For
example, interim results from the Collaborative Initial
Glaucoma Treatment Study showed that patients rand-
omized to either medical or surgical treatment for primary
open-angle glaucoma had comparable outcomes at five
years [20]. Such an approach has already been imple-
mented in some parts of India[21]. While longer term
data is needed before primary surgery can be more
broadly recommended, the higher initial cost may ulti-
mately prove to be justifiable in the long run for patients
in developing countries such as Nepal who face greater
obstacles to accessing health care resources. Similarly,
prophylactic laser peripheral iridotomy (LPI) has been
studied for the prevention and treatment of PACG in East
Asian and Indian populations, though which patients
would benefit most from this intervention is still being
defined [22-24].
As mentioned previously, a simple and cost-effective
screening plan for glaucoma has yet to be developed, a
point emphasized by a 2006 Cochrane review that could
not support population-based screening for primary
open-angle glaucoma due to the fact that no randomized
controlled trials could be identified.9 An analysis of data
obtained from the Baltimore Eye Survey failed to demon-
strate an acceptable balance of sensitivity and specificity
in the study population for several tests (either separately
or in combination) commonly used in the diagnosis of
glaucoma, including tonometry, stereoscopic fundus pho-
tography, and Humphrey visual field analysis [11] More
recent assessments of FDT perimetry as a screening tool in
both developed and developing countries have been
encouraging with good specificity for glaucoma; however,
the test appears to have low sensitivity, and thus may be
most beneficial as an adjunctive measure[25,26]. In light
of the continuing challenges regarding accurate and cost-
effective diagnosis of glaucoma in the general population
it has been suggested that health care providers focus their
Table 1: Data from Glaucoma Awareness Week (2004–2007)
2004 2005 2006 2007 Total
Total number registered 259 343 457 522 1581
Established glaucoma patients 145 (60%) 105 (30.6%) 231 (50.5%) 342 (65.5%) 823 (52.1%)
Newly diagnosed glaucoma patients 28 (10.8%) 38 (11.1%) 33 (7.2%) 21 (4.0%) 120 (7.6%)
Humphrey visual field analysis 129 137 235 203 704
FDT perimetry 123 53 42 147 365
Pachymetry 86 34 26 52 198
Optical coherence tomography - - 6 24 30
Disc photography 57 17 90 112 276
Bottles of medication distributed 51 87 264 368 770
Laser treatments 14 11 5 17 47
Patients supported for surgery 11 15 16 11 53
FDT = frequency doubling technology. Note that the quantity of medication distributed may not equal the number of glaucoma patients seen during 
a given year as not all established glaucoma patients received free medication in 2004 and 2005, and some patients received more than one sample 
in subsequent years. Similarly, some patients may have received both medication and another form of treatment (i.e. laser or surgery).
Table 2: Data from selected one day screening clinics (2006)
Bhotechaur Lele Badikhel
Total number registered 318 180 298
Total number ≥ 50 years of age 99 (31%) 85 (47%) 99 (33%)
Patients diagnosed with POAG 2 1 3
Patients diagnosed with PAC 2 1 2
Glaucoma suspects referred to TEC 10 6 7
Number of glaucoma suspects who followed up at TEC 8 6 7
Glaucoma suspects ultimately diagnosed with POAG 2 1 1
Total number diagnosed with POAG (incl. percent ≥ 50 years of age) 4 (4.0%) 2 (2.4%) 4 (4.0%)
POAG = primary open-angle glaucoma; PAC = primary angle closure; TEC = Tilganga Eye Centre.Page 5 of 7
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(e.g. older age, positive family history, or certain ethnic
groups) instead [10,12,27]. This is an issue that will con-
tinue to evolve as our understanding of glaucoma, as well
as diagnostic and therapeutic modalities, are further
refined.
Like other developing countries, human resource and
infrastructure development are critical to the success of
future glaucoma screening and treatment efforts in Nepal;
indeed, the development of such programs is meaningless
if a society has neither the manpower nor the equipment
and facilities with which to implement them. Presently,
participation in the outreach programs described here is
limited to villages near Kathmandu that have road access
to and from TEC, facilitating initial evaluation and follow-
up. Nepal has approximately 46 primary eye centers in
some of the more remote areas of the country that are
staffed by ophthalmic assistants trained to diagnose and
treat minor eye diseases and refer patients to one of the 18
larger district eye hospitals when necessary. It is crucial
that these providers are adequately trained in the diagno-
sis and effects of glaucoma as they may represent the only
opportunity for case detection and education in their
respective regions. TEC has previously conducted a glau-
coma training workshop for ophthalmic assistants and
continues to look for ways to improve such programs, as
well as to expand training to include general ophthalmol-
ogists from the district eye hospitals where similar pro-
grams for screening, treatment, and education may be
implemented if proven effective. Due in part to some of
the challenges discussed above, glaucoma was not
included as an avoidable cause of blindness in the VISION
2020 initiative, launched jointly in 1999 by WHO and the
International Agency for the Prevention of Blindness
(IAPB) [28]. Thus, it is incumbent upon eye care providers
and public health officials to ensure that glaucoma
remains a priority along with other more easily identifia-
ble and treatable eye diseases. It is our hope that this task
will be accomplished in part through the continued devel-
opment, refinement, and validation of sustainable clinical
and educational programs such as those described here.
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